Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Ramps Up R&D Investment for ADC, 16 Studies Added to DS-8201
November 1, 2019
- Takeda’s Underlying Revenue Skids 0.2% in 1st Half as Rare Disease Biz Weighs
November 1, 2019
- Despite a Hold by Key Panel, Ono Sees Cachexia Drug Launch in April-September 2020
November 1, 2019
- Astellas, Pandion Link Arms on Pancreas-Targeted Immunomodulators
November 1, 2019
- Xtandi Helps Astellas Counter Vesicare/Tarceva LOEs in April-September
November 1, 2019
- Edoxaban Drives Daiichi Sankyo’s Half-Year Earnings
November 1, 2019
- Satralizumab Accepted for Review in Europe, US; Chugai Plans Japan Filing Before Year-End
November 1, 2019
- Sumitomo, Roivant Ink Definitive Alliance Deal; Ex-Genentech Exec to Wield Baton
November 1, 2019
- Ono Checks In 3.2% Revenue Growth on Opdivo, Forxiga in 1st Half
November 1, 2019
- Shionogi to Snap Up UMN Pharma to Bolster Vaccine Biz
October 31, 2019
- Shionogi’s Half-Year Sales Slip 4.4% after Xofluza Milestone Gain
October 31, 2019
- Mitsubishi Tanabe to Give Another Try for Radicava’s EU OK, but in Oral Form: Chief
October 31, 2019
- Mitsubishi Tanabe Suffers 10% Sales Slide in 1st Half on Gilenya Royalty Row
October 31, 2019
- Taiwan Expands Hemlibra Label into Non-VIII Inhibitor Carriers
October 31, 2019
- Eisai Sees Brisk Sales of Global Brands, but Earnings Slump on One-Off Factors
October 31, 2019
- Eisai CEO Says Aducanumab Resurrection Was a Surprise, Touts Totality of Data as He Relays New Findings
October 31, 2019
- Taisho’s Prescription Drug Sales Suffer Double-Digit Decline in H1, due to Capital Tie-Up Dissolution with Toyama Chemical
October 31, 2019
- Taisho, Novartis to Stop Comarketing Lusefi at December-End
October 31, 2019
- Roche Going Beyond Oncology to Rev Up Precision Medicine Drive in Ophthalmology, Neuroscience
October 30, 2019
- AstraZeneca’s Japan R&D Chief Tapped as Medical Affairs SVP for Global Oncology Biz
October 30, 2019
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…